Sanders Morris Harris LLC acquired a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 18,600 shares of the company’s stock, valued at approximately $336,000. Other hedge funds have also bought and sold shares of the company. Tower […]
HC Wainwright reaffirmed their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note released on Monday, Benzinga reports. HC Wainwright currently has a $33.00 price objective on the stock. A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald restated an overweight rating […]
HC Wainwright reiterated their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report report published on Monday, Benzinga reports. The firm currently has a $33.00 price target on the stock. Other equities analysts have also recently issued research reports about the stock. JMP Securities cut their price objective on […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target upped by Oppenheimer from $40.00 to $46.00 in a report released on Monday morning, Marketbeat reports. The firm currently has an outperform rating on the stock. Other research analysts also recently issued reports about the company. HC Wainwright reissued a buy rating and issued a […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report)’s share price gapped up before the market opened on Tuesday after Evercore ISI raised their price target on the stock from $41.00 to $48.00. The stock had previously closed at $26.08, but opened at $27.00. Evercore ISI currently has an outperform rating on the stock. Crinetics Pharmaceuticals […]